Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature of this association was unclear. METHODS: We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case-control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. RESULTS: In nested case-control analyses from two prospective cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7). In two retrospective case-control cohorts for the evaluation of early-onset myocardial infarction, participants with CHIP had a risk of myocardial infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7). Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with coronary heart disease. CHIP carriers with these mutations also had increased coronary-artery calcification, a marker of coronary atherosclerosis burden. Hypercholesterolemia-prone mice that were engrafted with bone marrow obtained from homozygous or heterozygous Tet2 knockout mice had larger atherosclerotic lesions in the aortic root and aorta than did mice that had received control bone marrow. Analyses of macrophages from Tet2 knockout mice showed elevated expression of several chemokine and cytokine genes that contribute to atherosclerosis. CONCLUSIONS: The presence of CHIP in peripheral-blood cells was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That subjects with clonal hematopoiesis are more susceptible to develop nonhematological, most notably cardiovascular, disease”
From Aging of hematopoietic stem cells (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tet2 and Ppm1d mutant murine models have demonstrated an increased inflammatory signature in mutant macrophages, with heightened inflammatory cytokine production upon pro-inflammatory stimulation in vitro [31,32,69,70].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated IL-8 and IL-1β levels have been reported in patients with TET2 CH in the Pakistan Risk of Myocardial Infarction Study (PROMIS) [20,32]”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measured
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Self-citationMacrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Cited by
Items 801–900 of 1,015
A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs
Amir, M., & Javed, S. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.742802 · Cited by 32
“It was suggested that clonal hematopoiesis might be a controllable risk factor, either by using cholesterol-lowering medicines or targeting certain inflammatory processes (Jaiswal et al., 2017).”
BackgroundRamírez, R., Ceprián, N., Figuer, A., Valera, G., Bodega, G., Alique, M., & Carracedo, J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020215 · Cited by 31
Walsh, K. X., Raghavachari, N., Kerr, C. L., Bick, A. G., Cummings, S. R., Druley, T. E., Dunbar, C. E., Genovese, G., Goodell, M. A., Jaiswal, S., et al. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.841796 · Cited by 31
“In experimental hypercholesterolemia-prone mice engrafted with TET2−/− bone marrow (including myeloid-specific TET2 deficiency), larger atherosclerotic lesions were found when compared to those receiving control bone marrow (Jaiswal et al., 2017; Fuster et al., 2020).”
BackgroundSelf-citationAging-Related Vascular Inflammation: Giant Cell Arteritis and Neurological Disorders
Watanabe, R., & Hashimoto, M. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.843305 · Cited by 33
Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk
Haring, B., Wissel, S., & Manson, J. E. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01724-2 · Cited by 31
Kabir, I., Zhang, X., Dave, J. M., Chakraborty, R., Qu, R., Chandran, R. R., Ntokou, A., Gallardo‐Vara, E., Aryal, B., Rotllán, N., et al. (2023) · Nature Aging · doi:10.1038/s43587-022-00342-5 · Cited by 33
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
Kaur, J., Valisekka, S. S., Hameed, M., Bandi, P. S., Varma, S., Onwughalu, C. J., Ibrahim, H., & Mongia, H. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.004 · Cited by 36
“183 One study notes a prevalence of 22% of CHIP in patients with MM, but whether similar results are found in MGUS is still being determined.”
ResultAssociation of Somatic TET2 Mutations With Giant Cell Arteritis
Robinette, M. L., Weeks, L. D., Kramer, R. J., Agrawal, M., Gibson, C. J., Yu, Z., Sekar, A., Mehta, A., Niroula, A., Brown, J. T., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42738 · Cited by 30
Self-citationDevelopmental programming of adult haematopoiesis system
Balistreri, C. R., Garagnani, P., Madonna, R., Vaiserman, A., & Melino, G. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100918 · Cited by 28
Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review
Papa, V., Marracino, L., Fortini, F., Rizzo, P., Campo, G. C., Vaccarezza, M., & Sega, F. V. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082480 · Cited by 30
Clonal hematopoiesis of indeterminate potential and risk of neurodegenerative diseases
Liu, X., Xue, H., Wirdefeldt, K., Song, H., Smedby, K., Fang, F., & Liu, Q. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20001 · Cited by 29
Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer
Feng, Y., Yuan, Q., Newsome, R. C., Robinson, T. M., Bowman, R. L., Zuniga, A. N., Hall, K. N., Bernsten, C. M., Shabashvili, D. E., Krajcik, K. I., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230011 · Cited by 33
“This includes cardiovascular disease (Dorsheimer et al., 2019; Jaiswal et al., 2017; Mas-Peiro et al., 2020; Yokokawa et al., 2021), infections (Bolton et al.”
BackgroundAging and comprehensive molecular profiling in acute myeloid leukemia
Li, J., Cheng, W., Lin, X., Wen, L., Wang, K., Zhu, Y., Zhu, H., Chen, X., Zhang, Y., Yin, W., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319366121 · Cited by 38
“CH is not only closely associated with malignant blood diseases such as myelodysplastic syndromes (MDS), mye-loproliferative neoplasms, and AML (14) but also shows the risk of development toward other systemic diseases (15).”
BackgroundLim, J., Hubbard, A. K., Blechter, B., Shi, J., Zhou, W., Loftfield, E., Machiela, M. J., & Wong, J. Y. Y. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.036984 · Cited by 30
Clonal Hematopoiesis and Cardiovascular Outcomes in Older Women
Ezzat, D., Uddin, M. M., Xue, L., Pershad, Y., Zhang, S., Collins, J. M., Kitzman, J. O., Jaiswal, S., Desai, P. M., Kooperberg, C. L., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.058 · Cited by 32
“10,12,13,15,18,20,24 However, some studies have reported significant associations between DNMT3A CHIP and CVD. 10,17,63 This inconsistency in the literature may be partially influenced by cohort characteristics and experimental design.”
Self-citationHerbrich, S., Chaib, M., Anandhan, S., Andrewes, S. W., Nagarajan, A., Guan, B., Gandhi, N., Gilliam, J., Radovich, M., & Sharma, P. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.09.011 · Cited by 30
Rhee, J., Bolton, K. L., Gupta, D., Weeks, L. D., Bick, A. G., Tall, A. R., Walsh, K. X., Fuster, J. J., & Natarajan, P. (2026) · Circulation · doi:10.1161/cir.0000000000001404 · Cited by 37
Self-citationRed blood cell distribution width is associated with neuronal damage in acute ischemic stroke
Hong, R., Zhu, J. J., Li, Z., Yuan, J., Zhao, P., Ding, J., Fan, Q.-L., Yang, J., Liu, B., Cai, J., et al. (2020) · Aging · doi:10.18632/aging.103250 · Cited by 28
“CHIP was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice [33].”
BackgroundImmunotherapy in Myeloproliferative Diseases
Braun, L. M., & Zeiser, R. (2020) · Cells · doi:10.3390/cells9061559 · Cited by 37
Clonal Hematopoiesis in Hospitalized Elderly Patients With COVID‐19
Hameister, E., Stolz, S. M., Fuhrer, Y., Thienemann, F., Schaer, D. J., Nemeth, J., Schuepbach, R. A., Goede, J. S., Reinhart, S., Schmidt, A. E., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000453 · Cited by 28
“4 were reported if they affected genes recurrently mutated in CH and myeloid malignancies.(1,9) Non-parametric tests were used to calculate the significance of differences as indicated in the figure legend and was considered statistically significant if p values were <0.”
BackgroundMethodInfluentialMooney, L., Goodyear, C. S., Chandra, T., Kirschner, K., Copland, M., Petrie, M. C., & Lang, N. N. (2021) · Clinical Science · doi:10.1042/cs20200306 · Cited by 33
The possible role of mutated endothelial cells in myeloproliferative neoplasms
Farina, M., Russo, D., & Hoffman, R. (2021) · Haematologica · doi:10.3324/haematol.2021.278499 · Cited by 28
“In particular, JAK2V617F CHIP has been most frequently associated with an increased risk of developing cardiovascular diseases, thrombosis and coronary heart disease.(19) Furthermore, Cordua et al.”
BackgroundChemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential
Ryder, C. B., Kondolf, H. C., O'Keefe, M. E., Zhou, B., & Abbott, D. W. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167183 · Cited by 31
The tumor suppression theory of aging
Wolf, A. M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111583 · Cited by 30
“Clonal hematopoiesis without other hematologic abnormalities (CHIP), almost doubles risk for coronary heart disease (Jaiswal et al., 2017).”
BackgroundEmerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 30
“In turn, studies of clonal hematopoiesis revealed that interleukin-1β is involved in a process by which bone marrow activation accelerates atherosclerosis [90,91].”
BackgroundNowakowska, M. K., Kim, T., Thompson, M. T., Bolton, K. L., Deswal, A., Lin, S. H., Scheet, P. A., Wehner, M. R., & Nead, K. T. (2022) · American Journal of Hematology · doi:10.1002/ajh.26465 · Cited by 32
“mutations can increase the expression of pro-inflammatory cytokine and chemokine genes, which contribute to the development of atherosclerosis and correspond to plaque burden.(11,12) Importantly, inhibition of CHmediated signaling pathways has been shown to attenuate CVD risk.”
BackgroundDong, Q., Song, N., Qin, N., Chen, C., Li, Z., Sun, X., Easton, J. B., Mulder, H. L., Plyler, E. M., Neale, G. A. M., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01038-6 · Cited by 28
PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
Zhang, L., Hsu, J. I., & Goodell, M. A. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1018 · Cited by 34
“CH has since been found to be associated with an increased risk of hematologic malignancies (17), cardiovascular disease (65), and increased all-cause mortality (66).”
BackgroundEpigenetic regulation in myocardial infarction: Non-coding RNAs and exosomal non-coding RNAs
Fadaei, S., Zarepour, F., Parvaresh, M., Motamedzadeh, A., Zadeh, S. S. T., Sheida, A., Shabani, M., Hamblin, M. R., Rezaee, M., Zarei, M., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1014961 · Cited by 32
Genetic Modifiers of Sickle Cell Disease
Pincez, T., Ashley‐Koch, A. E., Lettre, G., & Telen, M. J. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.06.006 · Cited by 31
The crossroads of cancer therapies and clonal hematopoiesis
Singh, A., & Balasubramanian, S. K. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.006 · Cited by 28
Park, S. J., & Bejar, R. L. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0133-9 · Cited by 30
Clonal Hematopoiesis and therapy related MDS/AML
Desai, P. M., & Roboz, G. J. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.006 · Cited by 31
Naqvi, K. Z., Sasaki, K., Bravo, G. M., Piérola, A. A., Yilmaz, M. E., Short, N. J., Assi, R. E., Jabbour, E. J., Ravandi, F., Kadia, T. M., et al. (2019) · Cancer · doi:10.1002/cncr.32056 · Cited by 29
“Platelets: Median [range], ×10(9)/L 85 [5-783] 84 [5-432] 87 [6-783] Percentage of BM blasts: Median [range] 4 [0-19] 4 [0-19] 5 [0-18]”
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 29
Autoimmune disease in CMML-the chicken or the egg?
Ambinder, A. J., Miller, J. B., & Dezern, A. E. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.101136 · Cited by 29
Choi, B., Kang, C. K., Park, S., Lee, D., Lee, A., Ko, Y., Kang, S., Kang, K., Kim, S., Koh, Y., et al. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00866-1 · Cited by 28
Immunometabolism in atherosclerotic disorders
Fleetwood, A. J., Noonan, J. E., Gruta, N. L. L., Kallies, A., & Murphy, A. J. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00473-5 · Cited by 31
“Metabolic and epigenetic changes have been identified as contributors to HSC/HSPC dysfunction in clonal hematopoiesis of indeterminate potential, which has emerged as an independent risk factor for CVD 139 .”
Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis
Cau, R., & Saba, L. (2024) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-24-344 · Cited by 27
“Clonal hematopoiesis, the expansion of blood cell clones with certain genetic mutations, is associated with an increased risk of both hematological malignancies and atherosclerotic cardiovascular disease (95,103).”
Clonal Hematopoiesis of Indeterminate Potential and Progression of CKD
Vlasschaert, C., Pan, Y., Chen, J., Akwo, E. A., Rao, V., Hixson, J. E., Chong, M., Uddin, M. M., Yu, Z., Jiang, M., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000680 · Cited by 28
Self-citationHarrison, C. N., Barbui, T., Bose, P., Kiladjian, J., Mascarenhas, J. O., McMullin, M. F., Mesa, R. A., & Vannucchi, A. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00608-3 · Cited by 32
“It is well established that people with CHIP have increased rates of haematological malignancy, increased risk of cardiovascular disease (CVD) and worse all-cause mortality compared with those without CHIP 3,4 .”
Cellular Senescence, Inflammaging and Cardiovascular Disease
Zanders, L., Arifaj, D., Wagner, J. U. G., & Dimmeler, S. (2026) · Immunological Reviews · doi:10.1111/imr.70084 · Cited by 33
“While initially regarded primarily as a precursor to leukemia, CH has been shown to confer only a modest risk for hematologic malignancies but is strongly associated with a higher incidence and progression of cardiovascular disease [164–166].”
Mester, J. L., Jackson, S. A., Postula, K. J. V., Stettner, A. R., Solomon, S. R., Bissonnette, J., Murphy, P. D., Klein, R. T., & Hruska, K. S. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.12.003 · Cited by 28
Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
Gelosa, P., Castiglioni, L., Camera, M., & Sironi, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113895 · Cited by 28
Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population
Al‐Bari, M. A. A., Hossain, S., & Kudrat‐E‐Zahan, M. (2021) · World Journal of Radiology · doi:10.4329/wjr.v13.i1.1 · Cited by 32
Genetics of Myeloproliferative Neoplasms
Szybinski, J., & Meyer, S. C. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.12.002 · Cited by 29
Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular Disease
Yokokawa, T., Misaka, T., Kimishima, Y., Wada, K., Minakawa, K., Kaneshiro, T., Yoshihisa, A., Ikeda, K., & Takeishi, Y. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.01.001 · Cited by 27
“Mutations in JAK2 are associated with clonal hematopoiesis (CH) (1,2).”
BackgroundMacrophage Jak2 deficiency accelerates atherosclerosis through defects in cholesterol efflux
Dotan, I., Yang, J., Ikeda, J., Roth, Z., Pollock‐Tahiri, E., Desai, H. R., Sivasubramaniyam, T., Rehal, S., Rapps, J. A., Li, Y. Z., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03078-5 · Cited by 28
Rane, J. K., Frankell, A. M., Weeden, C. E., & Swanton, C. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0469 · Cited by 25
“Dominance by a few clones can reduce overall fitness and adaptability in histologically normal tissues, increasing its susceptibility to age-related diseases such as cancer (33,59,68–71).”
BackgroundKumrić, M., Urlić, H., Božić, J., Vilović, M., Kurir, T. T., Glavaš, D., Miric, D., Zanchi, J., Bradarić, A., Lozo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098062 · Cited by 28
Clonal hematopoiesis in survivors of childhood cancer
Friedman, D. N., Chan, I. C. C., Moskowitz, C. S., Li, S., Turner, K., Liu, J., Bouvier, N., Walsh, M. F., Spitzer, B. G., Kung, A. L., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009817 · Cited by 28
Leukocyte–endothelial interaction in CKD
Sarakpi, T., Mesic, A., & Speer, T. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad135 · Cited by 30
“Several clinical and experimen-talstudieshavedemonstratedtheassociationbetweenCHIPand a higher risk of all-cause mortality, CAD, myocardial infarction, heart failure and progression of atherosclerosis 155, [157–160].”
BackgroundEmbryonic vitamin D deficiency programs hematopoietic stem cells to induce type 2 diabetes
Oh, J., Riek, A. E., Bauerle, K. T., Dusso, A., McNerney, K. P., Barve, R. A., Darwech, I., Sprague, J., Moynihan, C., Zhang, R. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38849-z · Cited by 30
Extrinsic and intrinsic modulators of inflammation-resolution signaling in heart failure
Rao, A., Gupta, A., Kain, V., & Halade, G. V. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00276.2023 · Cited by 28
Gu, C., Pang, B., Sun, S., An, C., Wu, M., Wang, N., Yuan, Y., & Liu, G. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231184217 · Cited by 31
“101 In hypercholesterolemic mice, hematopoietic JAK2 V617F expression promoted early lesion formation with neutrophil infiltration and increased complexity in advanced AS with cellular defects in erythrocytes and macrophages.”
BackgroundSomatic mutations in human ageing: New insights from DNA sequencing and inherited mutations
Chatsirisupachai, K., & de Magalhães, J. P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102268 · Cited by 32
“That said, other ageing diseases besides cancer exhibit stochastic patterns, like clonal haematopoiesis of indeterminate potential, in turn a risk factor for cancer and cardiovascular disease (Jaiswal et al., 2017).”
BackgroundBabaev, V. R., Huang, J., Ding, L., Zhang, Y., May, J. M., & Linton, M. F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00215 · Cited by 29
“These results are consistent with the current concepts that low numbers of circulating monocytes and high sensitivity of macrophages to pro-apoptotic stimuli are key drivers that suppress atherogenesis (66, 67).”
ResultWang, X., Feng, Z., Li, Q., Yi, B., & Xu, Q. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2826-x · Cited by 28
Outcomes of percutaneous coronary interventions in cancer patients
Bharadwaj, A. S., Swamy, P. M., & Mamas, M. A. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1718493 · Cited by 27
“CHIP uniformly doubles their risk of CAD [17].”
BackgroundSellar, R. S., Jaiswal, S., & Ebert, B. L. (2018) · Nature Medicine · doi:10.1038/s41591-018-0114-7 · Cited by 29
Self-citationFrom clonal haematopoiesis to the CANTOS trial
Świrski, F. K. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.208 · Cited by 26
Tracking hematopoietic stem cells and their progeny using whole-genome sequencing
Lee-Six, H., & Kent, D. G. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.004 · Cited by 29
Li, J., Zhang, X., Yang, M., Yang, H., Xu, N., Fan, X., Liu, G., Jiang, X., Fan, J., Zhang, L., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01152-z · Cited by 28
“More recently, two landmark studies have independently demonstrated the important role of the hematopoietic DNA demethylating enzyme TET2 in preventing atherosclerosis by repressing pro-inflammatory cytokine and chemokine expression as well as inflammasome activation [38, 39].”
BackgroundImmunity, Vascular Aging and Stroke
Louka, A. M., Sagris, D., & Ntaios, G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220103101700 · Cited by 28
Ferrari, S., & Pesce, M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.791646 · Cited by 28
“, DNA methyltransferase-3α (DNMT-3A) and Tet Methylcytosine Dioxygenase-2 (TET-2)] (105) or cell cycle control (P53) (106), CHIP creates an imbalance in the amount of committed innate immunity cells with a pro-inflammatory phenotype, thus increasing the overall cardiovascular risk due to inflammation and accelerated s…”
BackgroundCardiac Calcifications: Phenotypes, Mechanisms, Clinical and Prognostic Implications
Sega, F. V. D., Fortini, F., Severi, P., Rizzo, P., Gardi, I., Cimaglia, P., Rapezzi, C., Tavazzi, L., & Ferrari, R. (2022) · Biology · doi:10.3390/biology11030414 · Cited by 32
“Human CHIP carriers have an increased risk of CAD and, possibly, of valvular diseases, such as calcific aortic stenosis [75].”
BackgroundCumbo, C., Tarantini, F., Zagaria, A., Anelli, L., Minervini, C. F., Coccaro, N., Tota, G., Impera, L., Parciante, E., Conserva, M. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.873896 · Cited by 26
“Individuals with CH have a higher incidence of HM, coronary heart disease, ischemic stroke, and heart failure (15).”
BackgroundA cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease
Wong, A., Hamidzada, H., & Epelman, S. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00701-0 · Cited by 32
Rajai, N., Ahmad, A., Toya, T., Sara, J. D. S., Herrmann, J., Lerman, L. O., & Lerman, A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac184 · Cited by 30
Lackraj, T., Barouch, S. B., Medeiros, J. J. F., Pedersen, S., Danesh, A., Bakhtiari, M., Hong, M., Tong, K. I., Joynt, J., Arruda, A., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26726 · Cited by 29
Dawoud, A. A. Z., Tapper, W., & Cross, N. C. P. (2023) · Science Advances · doi:10.1126/sciadv.ade9746 · Cited by 26
“Driver mutations were classified into myeloid or lymphoid according to a published list of genes associated with myeloid neoplasms (n = 76) (15) and genes associated with acute lymphoblastic leukemia or chronic lymphocytic leukemia in the Cancer Gene Census (61), respectively (table S1).”
BackgroundAndersson‐Assarsson, J. C., van Deuren, R. C., Kristensson, F. M., Steehouwer, M., Sjöholm, K., Svensson, P., Pieterse, M., Gilissen, C., Taube, M., Jacobson, P., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104621 · Cited by 28
Sikking, M. A., Stroeks, S. L. V. M., Henkens, M. T. H. M., Raafs, A. G., Cossins, B., van Deuren, R. C., Steehouwer, M., Riksen, N. P., van den Wijngaard, A., Brunner, H. G., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.06.037 · Cited by 31
An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk
Mohammadnia, N., Opstal, T. S. J., Messaoudi, S. E., Bax, W. A., & Cornel, J. H. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.08.016 · Cited by 30
Omics Approaches Unveiling the Biology of Human Atherosclerotic Plaques
Wu, X., & Zhang, H. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.12.007 · Cited by 29
“23 The underlying mechanisms of the association represent an active area of research.”
Backgroundp53 involvement in clonal hematopoiesis of indeterminate potential
Chen, S., & Liu, Y. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000509 · Cited by 30
Awada, H. K., Thapa, B., & Visconte, V. (2020) · Cells · doi:10.3390/cells9112512 · Cited by 31
“CHIP is also associated with an increased risk of cardiovascular disease and overall mortality [121,129].”
BackgroundMurine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease
Wang, Y., Sano, S., Ogawa, H., Horitani, K., Evans, M. A., Yura, Y., Miura‐Yura, E., Doviak, H., & Walsh, K. X. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab215 · Cited by 29
Editorial: Inflammation and chronic disease
Orlando, F. A., & Mainous, A. G. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1434533 · Cited by 30
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults
Gent, D. G., Saif, M. A., Dobson, R., & Wright, D. J. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.06.004 · Cited by 33
Ullrich, F., Bröckelmann, P. J., Turki, A. T., Khan, A., Chiru, E.-D., Vetter, M. H. F., von Tresckow, B., Wirth, R., Córdoba, R., Ortiz‐Maldonado, V., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009462 · Cited by 29
“29 Recently, lymphoid CHIP, defined as CHIP with mutations otherwise known from lymphoid malignancies, gained new interest.”
Clonal Hematopoiesis of Indeterminate Potential
Boettcher, S., & Ebert, B. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.3588 · Cited by 26
Self-citationSlavin, T. P., Teh, J. B., Weitzel, J. N., Peng, K., Wong, F. L., Qin, H., Wang, J., Wu, X., Mei, M. G., Pillai, R. K., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.08.013 · Cited by 25
“For example, one potential explanation for our findings is that CH involving myeloid genes may trigger accelerated aging or inflammatory pathways [18].”
Advances in therapeutic options for newly diagnosed, high-risk AML patients
Doucette, K., Karp, J. E., & Lai, C. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211001138 · Cited by 42
Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations
Leiva, O., Baker, O. N., Jenkins, A., Brunner, A. M., Al-Samkari, H. T., Leaf, R. K., Rosovsky, R. P. G., Fathi, A. T., Weitzman, J. I., Bornikova, L., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.19812 · Cited by 25
Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F
Misaka, T., Kimishima, Y., Yokokawa, T., Ikeda, K., & Takeishi, Y. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.001 · Cited by 28
Immune Cell Activation in Obesity and Cardiovascular Disease
Garcia, J. N., Wanjalla, C. N., Mashayekhi, M., & Hasty, A. H. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01222-4 · Cited by 25
Mas‐Peiró, S., Pergola, G., Berkowitsch, A., Meggendorfer, M., Rieger, M. A., Vasa‐Nicotera, M., Dimmeler, S., & Zeiher, A. M. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02135-7 · Cited by 28
“Clonal hematopoiesis of indeterminate potential (CHIP), driven by the presence of somatic mutations in hematopoietic cells in patients without other hematological abnormalities, has been shown to have an impact on mortality in patients with cardiovascular diseases [1], including coronary artery disease [2], heart fail…”
BackgroundResultInfluentialClonal Hematopoiesis and Acute Ischemic Stroke Outcomes
Lee, E., An, H. Y., Lim, J., Park, K., Choi, S., Jeong, H., Kang, D., Yang, W., Kim, J., Ko, S., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26754 · Cited by 26
“4,5 In gene-speci fi c analyses, PPM1D was surprisingly associated with the risk of incident stroke.”
BackgroundConvergent somatic evolution commences in utero in a germline ribosomopathy
Machado, H. E., Øbro, N. F., Williams, N., Tan, S., Boukerrou, A. Z., Davies, M., Belmonte, M., Mitchell, E., Baxter, E. J., Mende, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40896-5 · Cited by 26
“…mutations, copy number changes and rearrangements in 35 genes known to be associated with haematological malignancy 35 and clonal haematopoiesis 33,34 ( ASXL1, BCOR, CALR, CBL, CSF3R, CUX1, DNMT3A, EZH2, GATA2, GNAS, GNB1, IDH1, IDH2, JAK2, KIT, KRAS, MLL3, MPL, NF1, NFE2, NRAS, PHF6, PPM1D,…”
Grimes, K., Jeong, H., Amoah, A., Xu, N., Niemann, J., Raeder, B., Hasenfeld, P., Stober, C., Rausch, T., Benito, E., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01754-2 · Cited by 27
“12 and 13 and Supplementary Tables 9, 10 and 17).”
BackgroundInvasive Assessment of Coronary Artery Disease in Clonal Hematopoiesis of Indeterminate Potential
Heimlich, J. B., Raddatz, M. A., Wells, J., Vlasschaert, C., Olson, S., Threadcraft, M. A., Foster, K., Boateng, E., Umbarger, K., Su, Y. R., et al. (2024) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.123.004415 · Cited by 26
Self-citationKállai, A., Ungvari, Z. I., Fekete, M., Maier, A. B., Mikala, G., Andrikovics, H., & Lehoczki, A. (2024) · GeroScience · doi:10.1007/s11357-024-01374-y · Cited by 28
“However, the mechanisms underlying this association are not fully understood but may involve the pro-inflammatory effects of clonal hematopoietic cells, their migration to atherosclerotic lesions, and their contribution to both local and systemic inflammation [48–50, 56, 64, 67, 70, 79, 81].”
InfluentialImpact of DNA methylation programming on normal and pre-leukemic hematopoiesis
Langstein, J., Milsom, M. D., & Lipka, D. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.008 · Cited by 26
Blaes, A. H., Thavendiranathan, P., & Moslehi, J. J. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_208509 · Cited by 27
Somatic mutations and T-cell clonality in patients with immunodeficiency
Savola, P., Martelius, T., Kankainen, M., Huuhtanen, J., Lundgren, S., Koski, Y., Eldfors, S., Kelkka, T., Keränen, M. A. I., Ellonen, P., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220889 · Cited by 27
“In general, Illumina sequencers show a low error rate,(48) and we applied standard variant detection practices with multiple quality filters (such as VAF threshold and the requirement for at least seven supporting reads for the variant), similar to reports by others using capture sequencing technologies.(7,18,19,49,50…”
MethodPerner, F., & Armstrong, S. A. (2020) · Cells · doi:10.3390/cells9122721 · Cited by 26
“The occurrence of these mutations was found to be associated with an increased risk to develop myeloid malignancies as well as cardiovascular disease [75,79,80].”
BackgroundYamamoto, Y., Minami, M., Yoshida, K., Nagata, M., Miyata, T., Yang, T., Takayama, N., Suzuki, K. W., Okawa, M., Yamada, K., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020712 · Cited by 28
Goldman, E. A., Spellman, P. T., & Agarwal, A. (2023) · Molecular Case Studies · doi:10.1101/mcs.a006251 · Cited by 27
“Numerous studies have shown clone size is positively associated with risk of carcinogenesis and other adverse health events (Jaiswal et al. 2014, 2017; Abelson et al. 2018; Desai et al. 2018; Bolton et al. 2019).”
Cigarette smoke stimulates clonal expansion of Jak2V617F and Tet2-/- cells
Ramanathan, G., Chen, J. H., Mehrotra, N., Trieu, T., Huang, A., Mas, E., Mena, J. M., Bliss, B., Herman, D. A., Kleinman, M. T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210528 · Cited by 24
“CHIP not only presents an increased risk for developing hematologic malignancies but is also associated with a range of co-morbidities that involve inflammation such as cardiovascular disease (4, 5) and gout (6).”
Background
Metadata
- Authors
- Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberg, D., Libby, P., Kathiresan, S., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- ORCID
- Jaiswal, Siddhartha
- Natarajan, Pradeep
- Silver, Alexander J.
- Gibson, Christopher J.
- Bick, Alexander G.
- McConkey, Marie
- Gupta, Namrata
- Gabriel, Stacey
- Ardissino, Diego
- Baber, Usman
- Mehran, Roxana
- Danesh, John
- Saleheen, Danish
- Melander, Olle
- Sukhova, Galina K.
- Neuberg, Donna
- Libby, Peter
- Kathiresan, Sekar
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-13
- Volume
- 377
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6717509
- OpenAlex
- W2628145035
- Cited by
- 2,683
- References
- 37
- Citations by year
- 2026: 303 · 2025: 322 · 2024: 347 · 2023: 338 · 2022: 371 · 2021: 303 · 2020: 263 · 2019: 215 · 2018: 169 · 2017: 44
- FWCI
- 143.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL082945, R01HL080472, RC2HL101834, T32HL116324)
- National Human Genome Research Institute (U54HG003067)
- Fogarty International Center (RC1TW008485)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- clonal hematopoiesis of indeterminate potential, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, coronary artery calcification, TET2 mutation, DNMT3A, ASXL1, JAK2, somatic mutations, atherosclerosis, cytokines and chemokines, macrophages, bone marrow transplantation
- MeSH terms
- Animals, Coronary Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mutation, Risk, Case-Control Studies, Sequence Analysis, DNA, Mice, Knockout, Genetic Predisposition to Disease, Atherosclerosis, Mice, Exome, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.